QC Laboratory Deviations

In this case study, the incident was primarily identified through a series of unexpected results during the routine stability analysis of a drug product formulation. The symptoms included:Click to read…

During a routine audit of stability testing, analysts discovered discrepancies in the analytical results compared to the historical data of earlier batches. The laboratory faced the following symptoms:Click to read…

During a routine FDA inspection at a mid-sized pharmaceutical company, several deviations were identified related to stability analysis results for an oncology product. The primary symptoms included:Click to read the…

In our scenario, the symptoms began to surface through routine testing of a critical drug product. Quality Control analysts detected an increasing frequency of OOS results for a particular stability…

The initial detection of the unapproved chromatographic integration arose during a routine quality control audit. Analysts noted discrepancies between the chromatographic results produced and the expected outcomes based on historical…

In this case, the laboratory faced discrepancies in the testing records of a batch of a drug product under review. Symptoms indicated a lack of alignment between the physical test…

The incident began when a routine stability test yielded unexpected results. Sample results for a key product were consistently out of specification (OOS) for stability parameters, prompting an immediate investigation.…

During the FDA inspection, several warning signs indicated that an analyst training gap existed. These symptoms manifested as follows:Click to read the full article.

During a scheduled quality control audit, discrepancies in chromatographic results were noted when transferring an HPLC method from Laboratory A to Laboratory B. This was highlighted by:Click to read the…

Early detection of unauthorized method modifications is critical. Staff at the QC laboratory observed a series of unexpected results during an analytical method transfer of a new product line. Key…

In a fictitious mid-sized pharmaceutical company, Quality Control (QC) analysts noted discrepancies during routine potency testing of a newly formulated tablet. The QC team identified four batches consecutively showing OOS…

During a routine FDA inspection, alarming signals emerged indicating potential data integrity issues in the Quality Control (QC) laboratory. These symptoms included:Click to read the full article.